EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT)

Nitin Ohri, William R Bodner, Rafi Kabarriti, Viswanathan Shankar, Rasim Gucalp, Haiying Cheng, Balazs Halmos

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2025.01.005 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Nitin Ohri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York. Electronic address: ohri.nitin@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiotherapy, Intensity-Modulated, Positron-Emission Tomography. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Standard radiation therapy (RT) for locally advanced nonsmall cell lung cancer (LA-NSCLC) employs a uniform dose of approximately 60 Gy. Recent trials demonstrated that RT dose escalation may not improve outcomes and may cause added toxicity. We previously performed a single-arm trial testing a personalized, risk-adapted, and deintensified RT strategy. We now report findings from a randomized trial testing this novel approach. METHODS AND MATERIALS: Patients with LA-NSCLC with Eastern Cooperative Oncology Group performance status 0-2 were eligible for this trial. Metabolic tumor volume for each pulmonary tumor and involved lymph node was calculated using fludeoxyglucose PET. Participants were randomly assigned 1:1 to receive standard RT (60 Gy in 30 fractions delivered to pulmonary tumors and involved lymph nodes) versus dose-painted RT (55 Gy delivered to tumors and lymph nodes with metabolic volume exceeding 20 cm3 and 44-48 Gy to other lesions, all in 20 fractions). Concurrent chemotherapy and standard adjuvant therapy were given in both arms. The primary objective was to characterize patient-reported outcomes using Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events. Secondary objectives included comparing outcomes between study arms. RESULTS: Fifty patients were enrolled. The most common grade 3 patient-reported adverse events within 90 days of RT completion were dysphagia (38%), fatigue (38%), cough (32%), and wheezing (28%). The median progression-free survival duration is 18 months, and the median overall survival duration is 42 months. Progression-free survival and overall survival rates are similar across study arms (logrank P = .562 and .765, respectively). There have been 3 cases of in-field disease progression, with 1 in the control arm and 2 in the dose-painted arm. Grade 3-4 lymphopenia was reduced with dose-painted RT (48% vs 81%, chi-square P = .012). CONCLUSION: High-grade patient-reported toxicity in patients with LA-NSCLC who are treated with concurrent chemoradiotherapy is common. We found no evidence that risk-adapted RT de-escalation compromises clinical outcomes. Follow-up studies testing the ability of this approach to improve the safety profile of chemoradiotherapy are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiotherapy, Intensity-ModulatedPositron-Emission TomographyHumansMaleFemaleMiddle AgedAgedFluorodeoxyglucose F18Tumor BurdenPatient Reported Outcome MeasuresRadiotherapy DosageAdultAged, 80 and over

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York. Electronic address: ohri.nitin@gmail.com.
  • Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York.
  • Department of Epidemiology and Population Health, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York.
  • Department of Medical Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York.

Zitieren

APA

Ohri, N., Bodner, W. R., Kabarriti, R., Shankar, V., Gucalp, R., Cheng, H., & Halmos, B. (2025). Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT). International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.01.005

Vancouver

Ohri N, Bodner WR, Kabarriti R, Shankar V, Gucalp R, Cheng H, et al. Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT). International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.01.005

BibTeX
@article{Ohri2025,
  author = {Ohri, Nitin and Bodner, William R and Kabarriti, Rafi and Shankar, Viswanathan and Gucalp, Rasim and Cheng, Haiying and Halmos, Balazs},
  title = {Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT)},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2025.01.005}
}
Kostenlos starten →